Tag Archives: Vertex Pharmaceuticals

Vertex Pharmaceuticals (VRTX) Gets a Buy Rating from Citigroup

In a report released today, Robyn Karnauskas from Citigroup maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report), with a price target of $205. The company’s shares opened today at $165.90. According to TipRanks.com, Karnauskas is a 4-star

Cantor Fitzgerald Remains a Buy on Vertex Pharmaceuticals (VRTX)

Cantor Fitzgerald analyst Alethia Young reiterated a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report) today and set a price target of $217. The company’s shares opened today at $169.64. Young said: “. Reiterate overweight and $217 price target.

A Director at Vertex Pharmaceuticals is Exercising Options

Today it was reported that a Director at Vertex Pharmaceuticals (VRTX – Research Report), Bruce Sachs, exercised options to buy 10,000 VRTX shares at $34.24 a share, for a total transaction value of $342.4K. Following Bruce Sachs’ last VRTX Buy

Vertex Pharmaceuticals (VRTX) Receives a Buy from Oppenheimer

Oppenheimer analyst Hartaj Singh maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report) today and set a price target of $200. The company’s shares opened today at $168.43. Singh wrote: “Vertex (VRTX) reported two positive phase 3 efficacy

New Buy Rating for Vertex Pharmaceuticals (VRTX), the Healthcare Giant

In a report released today, Alethia Young from Cantor Fitzgerald maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report), with a price target of $217. The company’s shares closed yesterday at $167.40. Young wrote: “: $217 PT. Vertex

The EVP, CRO of Vertex Pharmaceuticals (NASDAQ: VRTX) is Buying Shares

Today, the EVP, CRO of Vertex Pharmaceuticals (VRTX – Research Report), Amit Sachdev, bought shares of VRTX for $364.1K. Following Amit Sachdev’s last VRTX Buy transaction on July 21, 2017, the stock climbed by 11.4%. Following this transaction Amit Sachdev’s